Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CUSTOM Study: Mevacor OTC Data May Be Boon For Switch Prospects

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Nonprescription Drugs Advisory Committee Chair and J&J/Merck consultant Brass says Mevacor actual use study data support safe use of OTC lovastatin. Almost half of high-risk patients reported using the nonprescription statin after discussing it with a doctor.

You may also be interested in...

OTC Mevacor Label Illustrates New Approach Toward Approval

Over-the-counter Mevacor label features marked differences from J&J/Merck’s proposal for 10 mg lovastatin in 2000. More specific directions reflect 20 mg dose as well as narrower range of potential users; 30% of U.S. adults could be candidates for OTC statins, researcher says.

Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors

The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts